Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA). The study will further evaluate a dose level of study drug (ARRY-371797) that has shown preliminary efficacy and safety in this patient population. After the primary analysis has been performed, eligible patients may receive open-label treatment with ARRY-371797.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Selected Key Inclusion Criteria:
Selected Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
77 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal